Piper Sandler Downgrades Aadi Bioscience to Neutral, Lowers Price Target to $1.75
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has downgraded Aadi Bioscience from Overweight to Neutral and reduced its price target from $5 to $1.75.

August 27, 2024 | 2:46 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Piper Sandler downgraded Aadi Bioscience from Overweight to Neutral and lowered the price target from $5 to $1.75, indicating a less optimistic outlook.
The downgrade from Overweight to Neutral by Piper Sandler suggests a less favorable view on Aadi Bioscience's stock, likely leading to a negative short-term impact on its stock price. The significant reduction in the price target from $5 to $1.75 further supports this outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100